Company Overview and News

43
Closing Bell: Sensex up over 300 pts, midcaps underperform; IT zooms, ONGC dips

2018-05-25 moneycontrol
Benchmark indices rose, driven by IT stocks, such as, Infosys and TCS on the back of a weak rupee. The IT index has gained 18 percent so far this year. The rupee has weakened by more than 7 percent so far this year, as surging crude oil prices weigh on India, the world’s third-largest importer, raising fears that soaring costs could drive up inflation and widen the trade deficit.
500325 JIPKY MS.PRE MS.PRF 531548 MS.PRG MS.PRA 534976 533207 AJANTPHARM BJJQY MS 500570 RLNIY AXB 524804 JETAIRWAYS 531335 AXBA BAJFINANCE MS.PRI FORTIS MS.PRK SOMANYCERA AUROPHARMA RELIANCE 532617 533155 BHRQY JUBLFOOD 532215 AXISBANK RIGD JBLWY BHARTIARTL 505324 TATAMOTORS MANUGRAPH 500034 IBN JPASSOCIAT 532843 AXBKY 532532 532454 VMART ICICIBANK 532331 JPINFRATEC 532174 ARBQY ZYDUSWELL TTM

0
Manugraph India board approves merger scheme

2018-05-08 thehindubusinessline
The board of Manugraph India on Tuesday considered and approved a scheme of merger. The scheme entails absorption of Constrad Agencies (Bombay) Pvt Ltd, and Maiu Enterprises and Santsu Finance and Investment Pvt Ltd with Manugraph India. The scheme is subject to sanction from the National Company Law Tribunal, approvals from the stock exchanges, SEBI, the respective shareholders and creditors of the amalgamating and amalgamated companies and such other statutory or regulatory approvals, the company said in a notice to the stock exchanges.
505324 MANUGRAPH

0
Manugraph India Limited - Outcome of Board Meeting

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505324 MANUGRAPH

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

1h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...